NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Wednesday, April 24, 2024 19:58

Release 4.98
Intubeaze® 20 mg/ml Laryngopharyngeal Spray Solution for Cats
 
Species: Cats
Therapeutic indication: Pharmaceuticals: Neurological preparations: Local anaesthetics
Active ingredient: Lidocaine hydrochloride monohydrate
Product:Intubeaze® 20 mg/ml Laryngopharyngeal Spray Solution for Cats
Product index: Intubeaze 20 mg/ml Laryngopharyngeal Spray Solution for Cats
Incorporating:
Qualitative and quantitative composition
1 ml contains: Active substance:
Lidocaine hydrochloride monohydrate 20 mg
(equivalent to lidocaine 16.2 mg)
Each actuation (0.14 ml) contains 2.8 mg of lidocaine hydrochloride monohydrate, which corresponds to 2.27 mg of lidocaine.
Excipients: Chlorocresol 1 mg
Pharmaceutical form
Laryngopharyngeal spray, solution. Clear, colourless liquid.
Clinical particulars
Target species
Cats.
Indications for use
Local anaesthesia of the laryngeal mucosa of the cat in order to facilitate endotracheal intubation by preventing stimulation of the laryngeal reflex.
Contraindications
Do not use in animals which are hypovolaemic or show heart block. Do not use in known cases of hypersensitivity to the active substance or any of the excipients.
Special warnings for each target species
Laryngeal spasm can also be stimulated by removal of the endotracheal tube. This should be carried out while the patient is still under anaesthesia.
Special precautions for use in animals
Use with care in cases with hepatic and or cardiac insufficiency.
It is advisable to cold sterilise the nozzle between uses to avoid the spread of infection.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
- Lidocaine and chlorocresol may cause hypersensitivity (allergic) reactions. People with known hypersensitivity to these substances should avoid contact with the product.
- Accidental exposure to this product may lead to local effects such as numbing, and systemic effects, such as dizziness or drowsiness. Accidental exposure, particularly oral, eye and inhalation exposure, should be avoided.
- Wear gloves when handling the product and wash any exposed areas after use. If accidental exposure to eyes occurs, rinse with water.
- In cases of severe or extended reactions, seek medical advice and show the label to the physician.
- Lidocaine can form genotoxic and mutagenic metabolites in humans. These metabolites can also induce, in long-term toxicology studies in rats, carcinogenic effects at high doses.
Use during pregnancy, lactation or lay
Laboratory studies in mice have shown evidence of foetotoxic effects at high doses.
No safety studies have been conducted with the product in pregnant queens.
Use only accordingly to the benefit / risk assessment by the responsible veterinarian.
Amounts to be administered and administration route
For laryngopharyngeral use.
Give one or two sprays at the back of the throat.
Prior to use, prime the pump until liquid is released. Minimum of 4 sprays are recommended for priming the bottle before first use and at least 2 sprays are recommended for re-priming if unused for 7 days or longer.
Each spray (approximately 0.14 ml) contains approximately 2.8 mg of lidocaine hydrochloride monohydrate, which corresponds to 2.27 mg of lidocaine.
Allow 30-90 seconds before attempting intubation, so that the larynx is relaxed.
It should be noted that when removing the actuator from the spray pump it should be done vertically and not at an angle to ensure the pin does not get damaged.
Overdose
Maintain a patent airway and support ventilation with oxygen.
Pharmacological particulars
Pharmacotherapeutic group: Throat preparations, local anaesthetic, lidocaine
ATCvet code: QR02AD02
Pharmacodynamic properties
Lidocaine acts by preventing the generation and conduction of nerve impulses. It prevents the increase in permeability of excitable membrances to sodium ions. Small, non-myelinated nerve fibres are more susceptible than are large fibres and the sensation of pain is the first modality to be lost. The product has a duration of action of approximately 15 minutes.
Pharmacokinetic properties
Lidocaine is metabolised mainly in the liver and excreted via the kidneys. Approximately 95% is excreted via the form of various metabolites while 5% is excreted unchanged.
Pharmaceutical particulars
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years
Shelf life after first opening: 3 months
Special precautions for storage
Do not store above 25°C.
Immediate packaging
A clear, colourless Type I glass vial with a polypropylene and polyethylene spray pump and actuator containing 10 ml. Vials are packaged in a cardboard box.
Disposal
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
Dechra Limited, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW, United Kingdom.
Marketing Authorisation Number
Vm 10434/4093
Significant changes
Date of the first authorisation or date of renewal
1 November 2018
Date of revision of the text
February 2023
Any other information
For animal treatment only. To be supplied only on veterinary prescription. Keep out of the sight and reach of children.
Legal category
Legal category: POM-V
GTIN
GTIN description:Intubeaze 20 mg/ml Laryngopharyngeal Spray Solution for Cats:
GTIN:05701170426113